drugset / Trial / NCT06814964
rhTNK-tPA Thrombolytic Removal of Intraventricular Hemorrhage
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this pilot study is to determine the safety and optimal dose of clot lysis with rhTNK-tPA for intraventricular hemorrhage, using stereotactic guidance for extraventricular drain placement.
Timeline
- Start
- 2025-03-01
- Primary completion
- 2025-05-01
- Completion
- 2025-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tenecteplase | Protein / enzyme biologic | 0.009 mg/ml | Other |
| Subject | Tenecteplase | Protein / enzyme biologic | 0.018 mg/ml | Other |
| Subject | Tenecteplase | Protein / enzyme biologic | 0.027 mg/ml | Other |